Processa pharmaceuticals announces positive efficacy results from preliminary evaluation of phase 1b dose-escalating trial with ngc-cap in gastrointestinal cancer

Eight of 12 evaluable patients (66.7%) had progression-free survival (pfs) ranging  from 5 to 11 months at the highest ngc-cap dose, all three evaluable patients had pfs with two partial responses (pr) and one stable disease (sd) for all ngc-cap doses, 5-fluorouracil (5-fu) exposure was greater and fluoro-beta-alanine (fbal) exposure was lower with a better or similar side-effect profile than monotherapy capecitabine hanover, md., june 11, 2024 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (processa or the company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed phase 1b clinical trial which defined the maximum tolerated dose (mtd) and recommended phase 2 dose range (rp2dr) for next generation capecitabine (ngc-cap) administered to patients with stage iii or iv gastrointestinal tract (gi) cancer.
PCSA Ratings Summary
PCSA Quant Ranking